1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Bajaj Healthcare Ltd

Bajaj Healthcare Ltd

BAJAJHCARE.NS
Bajaj Healthcare LtdIN flagNational Stock Exchange of India
348.70
INR
-1.40
- -
11.74BMarket Cap
Bajaj Healthcare Ltd
BAJAJHCARE.NS
(National Stock Exchange of India)

Recent

price

348.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
43.43
51.27
61.88
74.01
78.51
82.53
74.28
104.02
117.13
147.74
237.62
246.35
234
171.35
182.58
193.01
181.12
Revenue per Share
1.54
0.24
-0.38
0.71
2.72
3.04
2.84
5.5
5.91
9.14
30.11
25.87
15.59
-30.36
13.29
4.98
14.32
Basic EPS, GAAP
-4.5
-3.09
-0.63
2.44
3.44
-2.05
4.36
1.85
3.68
-0.77
-25.45
-28.49
-41.95
22.47
3.39
4.65
- -
Free Cash Flow per Basic Share
- -
0.1
- -
- -
- -
- -
- -
- -
0.25
- -
0.88
0.5
1.5
1
0.93
1
- -
Dividend per Share
7.58
7.82
7.44
8.15
10.87
15.57
18.44
23.94
52.98
64.55
93.79
119.16
133.24
101.88
107.65
5.32
- -
Book Value per Share
10.23
10.47
10.08
10.8
13.52
32.83
35.95
41.17
55.39
64.47
93.63
119.02
132.73
100.2
156.39
168.05
- -
Tangible Book Value per Share
28
28
28
28
28
27
28
28
28
28
28
28
28
28
30
32
31
Basic Weighted Avg Shares
1,199
1,415
1,708
2,042
2,167
2,228
2,046
2,871
3,233
4,078
6,558
6,799
6,458
4,729
5,426
6,110
5,592
Sales/Revenue/Turnover
7.52
4.02
2.75
5.09
9.16
9.84
9.59
-9.07
10.65
11.44
18.48
15.31
14.6
10.3
10.05
12.65
9.94
Operating Margin (%)
47
56
81
89
89
93
113
111
114
121
161
176
274
314
279
275
268
Depreciation Expense
45
7
-11
20
75
82
78
152
163
252
831
714
430
-838
395
158
442
Net Income, GAAP
23.69
38.15
- -
40.07
37.46
39.25
- -
33.05
32.52
30.02
30.05
20.4
18.74
- -
6.69
26.32
6.5
Effective Tax Rate (%)
3.73
0.46
-0.62
0.97
3.47
3.68
3.83
5.29
5.05
6.19
12.67
10.5
6.66
-17.72
7.28
2.58
7.9
Profit Margin (%)
-80
-108
-128
-128
-52
-101
-15
85
130
308
758
762
668
386
2,639
3,065
- -
Working Capital
120
174
171
145
222
314
268
215
174
236
797
663
944
391
649
506
- -
LT Debt
297
304
293
313
388
886
990
1,136
1,529
1,779
2,584
3,285
3,677
2,784
4,662
5,330
- -
Total Equity
- -
4.03
- -
6.05
11.5
9.42
- -
-9.54
10.84
13.16
24.02
15.92
10.92
- -
7.86
7.74
- -
Return on Invested Capital (%)
- -
4.64
- -
6.74
12.8
11.09
- -
14.57
11.12
12.05
25.1
15.63
8.23
- -
11.33
7.95
18.13
Return on Capital (%)
- -
3.06
-5.02
9.17
28.63
22.76
16.86
25.99
15.37
15.56
38.04
24.29
12.35
-25.83
13.14
9.36
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
1,583
- -
LT Borrowings
- -
647
- -
LT Finance Leases
- -
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
32
- -
Market Capitalization
16,785
20,006
15,558

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
5,609
- -
Cash, Cash Equivalents & STI
- -
379
- -
Accounts Receivable, Net
- -
2,517
- -
Inventories
- -
1,619
- -
Total Current Liabilities
- -
2,970
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,583
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.92%
19.31%
14.34%
Free Cash Flow
269.35%
-26.39%
46.12%
Net Income, GAAP
-17.49%
-111.16%
-60.08%
Sales/Revenue/Turnover
13.1%
-0.15%
12.61%
Total Cash Common Dividend
- -
- -
14.44%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,297
1,012
1,086
1,339
4,729
2025
1,322
1,331
1,228
1,545
5,426
2026
1,488
1,612
1,531
- -
6,110

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-17.47
-1.25
-0.8
- -
-30.36
2025
2.59
3.36
3.65
3.54
13.29
2026
3.74
4.96
-7.16
- -
4.98

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
0.93
2026
- -
- -
- -
- -
1
Similar Companies
Copland Road Capital Corporation (CRCC.CN)
Eco-Growth Strategies Inc. (ECGS)
iAnthus Capital Holdings, Inc. (IAN.CN)
LFTD Partners Inc. (LIFD)
Sofgen Pharma S.A. (PRCWF)
Ecofibre Limited (EOFBY)
Business
Bajaj Healthcare Limited (BAJAJHCARE.NS), incorporated in 1993 and headquartered in Thane, Maharashtra, India, manufactures active pharmaceutical ingredients (APIs), intermediates, finished dosage formulations (FDFs), and nutraceutical products for pharmaceutical, nutraceutical, and food industries worldwide. The company produces a diverse range of APIs including chlorhexidine and its derivatives, fosfomycin salts (calcium, sodium, trometamol), carbamazepine, oxcarbazepine, deferasirox, citicoline sodium, ascorbic palmitate, octenidine dihydrochloride, hesperidin, and diosmin; intermediates essential for API and FDF processes; FDFs such as tablets, capsules, powders, and sachets; and nutritional supplements like amino acids; with manufacturing facilities across Gujarat and Maharashtra, including 15 API plants certified under USFDA, EU-GMP, KFDA, WHO-GMP, and others, enabling exports to over 60 countries primarily in the US, Europe, Africa, and Australia. Bajaj Healthcare operates as India's largest producer of ascorbic acid and the world's largest manufacturer of chlorhexidine base, while serving as the sole private entity processing opium gum and poppy straw under government contracts, with a new facility handling 250 MT opium gum and 2,500 MT poppy straw annually. In recent developments, the company acquired GenRx Pharmaceuticals Private Limited for ₹10.85 crore in April 2025 to expand formulations manufacturing capabilities at a WHO-GMP-certified facility in Nashik producing tablets, capsules, and nasal sprays, subject to regulatory approvals expected within 3-6 months; signed definitive CDMO agreements with UK and EU customers for exclusive development and supply of 15 APIs; launched new molecules in nutraceuticals, APIs, and formulations; filed 41 DMFs in FY24; and sold a Tarapur plant to reduce debt, anticipating further asset sales by late FY25 to bolster financial position amid market challenges.